We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
- Recent ZBH Stock Price: $137.91
- Yearly Gain for ZBH stock: 12.42%
- Market Cap for ZBH stock: $28.70B
- P/E Ratio for ZBH stock: 63.953
Will ZBH's stock price go up? Is there an accurate ZBH stock forecast available?
TipRanks.com reports that Zimmer Biomet Holdings currently has 20 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $147.89. The target pricing ranges from a high ZBH forecast of $172.00 down to a low forecast of $112.00. Zimmer Biomet Holdings (ZBH)’s last closing stock price was $137.91 which would put the average price target at 7.24% upside.
In addition, TradingView issued a Buy rating for ZBH stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ZBH stock.
Other analysts covering ZBH include:
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 160 on 2 days ago
- Kyle Rose of Canaccord Genuity issued a Hold rating with the price target of $ 150 on 2 days ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 150 on 2 days ago
- Travis Steed of Bank of America Securities issued a Hold rating with the price target of $ 160 on 2 days ago
If you are wondering if ZBH is a good stock to buy, here are 3rd party ratings for ZBH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Top 38% (96 out of 250)
What is the sentiment on the street regarding Zimmer Biomet Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for ZBH stock: Very Bullish
- Blogger Consensus for ZBH stock: Bullish
- Media Buzz for ZBH stock: Very High
- Insider Signal for ZBH stock: ―
- Investor Sentiment for ZBH stock: Negative
- Hedge Fund signal for ZBH stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ZBH stock including scouring the social networks like ZBH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ZBH stock chart >>
Summary: Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.
- Recent VRTX Stock Price: $348.09
- Yearly Gain for VRTX stock: 30.12%
- Market Cap for VRTX stock: $89.26B
- P/E Ratio for VRTX stock: 27.609
Will VRTX's stock price go up? Is there an accurate VRTX stock forecast available?
TipRanks.com reports that Vertex Pharmaceuticals currently has 22 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $366.75. The target pricing ranges from a high VRTX forecast of $456.00 down to a low forecast of $305.00. Vertex Pharmaceuticals (VRTX)’s last closing stock price was $348.09 which would put the average price target at 5.36% upside.
In addition, TradingView issued a Buy rating for VRTX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRTX stock.
Other analysts covering VRTX include:
- Jessica Fye of J.P. Morgan issued a Buy rating with the price target of $ 345 on 3 days ago
- Unknown Analyst of Bernstein issued a Buy rating with the price target of $ 363 on 3 days ago
- Unknown Analyst of Barclays issued a Buy rating with the price target of $ 384 on 3 days ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 380 on 3 days ago
If you are wondering if VRTX is a good stock to buy, here are 3rd party ratings for VRTX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 38% (96 out of 250)
What is the sentiment on the street regarding Vertex Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRTX stock: Very Bullish
- Blogger Consensus for VRTX stock: Bullish
- Media Buzz for VRTX stock: Very Low
- Insider Signal for VRTX stock: ―
- Investor Sentiment for VRTX stock: Positive
- Hedge Fund signal for VRTX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on VRTX stock including scouring the social networks like VRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRTX stock chart >>
Summary: Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic'products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg'products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.
- Recent SYK Stock Price: $284.71
- Yearly Gain for SYK stock: 18.23%
- Market Cap for SYK stock: $108.05B
- P/E Ratio for SYK stock: 42.771
Will SYK's stock price go up? Is there an accurate SYK stock forecast available?
TipRanks.com reports that Stryker currently has 20 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $313.16. The target pricing ranges from a high SYK forecast of $345.00 down to a low forecast of $285.00. Stryker (SYK)’s last closing stock price was $284.71 which would put the average price target at 9.99% upside.
In addition, TradingView issued a Neutral rating for SYK stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SYK stock.
Other analysts covering SYK include:
- Pito Chickering of Deutsche Bank issued a Hold rating with the price target of $ 292 on 3 days ago
- Unknown Analyst of Barclays issued a Buy rating with the price target of $ 321 on 3 days ago
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 342 on 3 days ago
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $ 315 on 3 days ago
If you are wondering if SYK is a good stock to buy, here are 3rd party ratings for SYK stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 38% (96 out of 250)
What is the sentiment on the street regarding Stryker? (Current ratings compiled by TipRanks.com)
- News Sentiment for SYK stock: Very Bullish
- Blogger Consensus for SYK stock: Bullish
- Media Buzz for SYK stock: Very High
- Insider Signal for SYK stock: Negative
- Investor Sentiment for SYK stock: Positive
- Hedge Fund signal for SYK stock: Neutral
The stock market is extremely volatile, and you need to do your own research on SYK stock including scouring the social networks like SYK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SYK stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================